M. Eugenia Socías, MD, MSc; Evan Wood, MD, PhD
Acknowledgment: The authors thank Jennifer Navin for her administrative assistance and Leo Beletsky for his legal advice.
Financial Support: Dr. Wood is a Tier 1 Canada Research Chairholder. Dr. Socías is supported by postdoctoral fellowship awards from the Michael Smith Foundation for Health Research and the Canadian Institute for Health Research.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2373.
Requests for Single Reprints: Evan Wood, MD, PhD, British Columbia Centre on Substance Use, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada; e-mail, bccsu-ew@cfenet.ubc.ca.
Current Author Addresses: Drs. Socías and Wood: British Columbia Centre on Substance Use, 608-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.
Author Contributions: Conception and design: M.E. Socías, E. Wood.
Analysis and interpretation of the data: M.E. Socías, E. Wood.
Drafting of the article: M.E. Socías.
Critical revision for important intellectual content: M.E. Socías, E. Wood.
Final approval of the article: M.E. Socías, E. Wood.
Socías ME, Wood E. Evaluating Slow-Release Oral Morphine to Narrow the Treatment Gap for Opioid Use Disorders. Ann Intern Med. 2018;168:141–142. [Epub ahead of print 26 December 2017]. doi: https://doi.org/10.7326/M17-2373
Download citation file:
© 2019
Published: Ann Intern Med. 2018;168(2):141-142.
DOI: 10.7326/M17-2373
Published at www.annals.org on 26 December 2017
Tobacco, Alcohol, and Other Substance Abuse.
Results provided by: